CT antigens are promising targets for immunotherapy in cancer because their expression is restricted to cancer and germ line cells and a proportion of cancer patients presents with immune responses against CT antigens, which clearly demonstrates their immunogenicity.

Pathology

MAGE-C2/CT10 could be a potential target for adjuvant and palliative immunotherapy in patients with prostate cancer. (21754986)